The crossword integrates recent dermatology news, including treatments, research, and trends, to reinforce professional knowledge.
Dermatology Times offers both interactive and static crossword formats for user convenience.
The Weekly Roundup provides in-depth analysis of significant dermatology stories and updates from the past week.
Following Dermatology Times content helps professionals stay informed and prepared for future crosswords.
SHOW MORE
Test your knowledge of key words and terms associated with dermatology news from the previous week.
Welcome to Dermatology Times' Sunday Crossword, where dermatology knowledge meets fun! Each week, we curate a selection of words and terms pulled directly from the latest news in the dermatology world. Whether it's breakthrough treatments, new research findings, or emerging trends, this crossword serves as both a challenge and an opportunity to reinforce your expertise in the field.
For more in-depth insights, don't forget to check out our Weekly Roundup, where we break down the most important stories and updates from the past week. And to stay ahead of the curve and prepare for future crosswords, make sure to follow our content throughout the week.
Try out either our interactive crossword or a static/non-interactive version below.
5. A recent study found that vitiligo patients had a higher incidence of this disease compared to those with psoriasis or atopic dermatitis.
6. A 5-year study backed the safety and efficacy of this TYK2 inhibitor in sustaining PASI 75 and PASI 90 responses.
7. (3 letters) This injectable treatment has shown effectiveness as both a standalone and combination therapy for rosacea.
9. The co-founder of PathAI, Andy Beck, MD, PhD, believes AI will be invaluable for dermatologists and these specialists.
Down
1. This dermatological condition, often triggered by laser treatments, was successfully treated using a combination of low-fluence Q-switch laser and tranexamic acid.
2. (5 letters) This type of therapy, endorsed by an expert panel, has been confirmed as a safe and effective treatment for nonmelanoma skin cancer.
3. The recent DELTA TEEN study highlighted the potential of this topical treatment for chronic hand eczema.
4. A new study found that the majority of US adults distrust the health care system’s use of this technology.
5. This oral BD2-selective BET inhibitor is advancing in a phase 1b trial for moderate to severe plaque psoriasis.
8. A study revealed that Hispanic and non-White patients with psoriatic arthritis had a higher burden of this symptom.
For answers to this week's puzzle, check out next week's edition of the Dermatology Times Sunday Crossword.